Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.

Davies, Andrew J; Barrans, Sharon; Stanton, Louise; Caddy, Josh; Wilding, Sam; Saunders, Geoff; Mamot, Christoph; Novak, Urban; McMillan, Andrew; Fields, Paul; Collins, Graham P; Stephens, Richard; Cucco, Francesco; Sha, Chulin; van Hoppe, Moniek; Tooze, Reuben; Davies, John R; Griffiths, Gareth; Schuh, Anna; Burton, Catherine; ... (2023). Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(15), pp. 2718-2723. American Society of Clinical Oncology 10.1200/JCO.23.00033

[img]
Preview
Text
jco.23.00033.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (245kB) | Preview

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The REMoDL-B phase III adaptive trial compared rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) versus R-CHOP + bortezomib (RB-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL), stratified by molecular subtype. Primary analysis at a median follow-up of 30 months found no effect of bortezomib on progression-free survival (PFS) or overall survival (OS). Retrospective analysis using a gene expression-based classifier identified a molecular high-grade (MHG) group with worse outcomes. We present an updated analysis for patients successfully classified by the gene expression profile (GEP). Eligible patients were age older than 18 years with untreated DLBCL, fit enough for full-dose chemotherapy, and with adequate biopsies for GEP. Of 1,077 patients registered, 801 were identified with Activated B-Cell (ABC), Germinal Center B-cell, or MHG lymphoma. At a median follow-up of 64 months, there was no overall benefit of bortezomib on PFS or OS (5-year PFS hazard ratio [HR], 0.81; P = .085; OS HR, 0.86; P = .32). However, improved PFS and OS were seen in ABC lymphomas after RB-CHOP: 5-year OS 67% with R-CHOP versus 80% with RB-CHOP (HR, 0.58; 95% CI, 0.35 to 0.95; P = .032). Five-year PFS was higher in MHG lymphomas: 29% versus 55% (HR, 0.46; 95% CI, 0.26 to 0.84). Patients with ABC and MHG DLBCL may benefit from the addition of bortezomib to R-CHOP in initial therapy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Novak, Urban

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1527-7755

Publisher:

American Society of Clinical Oncology

Language:

English

Submitter:

Pubmed Import

Date Deposited:

28 Mar 2023 09:45

Last Modified:

19 May 2023 00:14

Publisher DOI:

10.1200/JCO.23.00033

PubMed ID:

36972491

BORIS DOI:

10.48350/180764

URI:

https://boris.unibe.ch/id/eprint/180764

Actions (login required)

Edit item Edit item
Provide Feedback